Yellow Fever - Pipeline Review, H1 2012

Yellow Fever – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Yellow Fever - Pipeline Review, H1 2012', provides an overview of the Yellow Fever therapeutic pipeline. This report provides information on the therapeutic development for Yellow Fever, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Yellow Fever. 'Yellow Fever - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Yellow Fever.
- A review of the Yellow Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Yellow Fever pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Yellow Fever.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Yellow Fever pipeline depth and focus of Yellow Fever therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Yellow Fever Therapeutic Products under Development, Key Players in Yellow Fever Therapeutics, Yellow Fever Pipeline Overview, Yellow Fever Pipeline, Yellow Fever Pipeline Assessment SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Yellow Fever Overview
Therapeutics Development
An Overview of Pipeline Products for Yellow Fever
Yellow Fever Therapeutics under Development by Companies
Yellow Fever Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Yellow Fever Therapeutics – Products under Development by Companies
Yellow Fever Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Yellow Fever Therapeutics Development
Alfacell Corporation
Crucell N.V.
iBio, Inc.
Xcellerex, Inc.
Yellow Fever – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Flavimun - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XRX-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Yellow Fever Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Squalamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rAmphinase 2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Yellow Fever Therapeutics – Drug Profile Updates
Yellow Fever Therapeutics - Dormant Products
Yellow Fever – Product Development Milestones
Featured News & Press Releases
Sep 19, 2011: Georgetown University Medical Center Researcher Proves Shark Compound To Be Potential Drug To Treat Human Viruses
Apr 07, 2011: Xcellerex Announces Positive Results From Phase I Clinical Trial Of XRX-001
Aug 10, 2010: New Hope in Finding Cure for Yellow Fever
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Yellow Fever, H1 2012
Products under Development for Yellow Fever – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Alfacell Corporation, H1 2012
Crucell N.V., H1 2012
iBio, Inc., H1 2012
Xcellerex, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Yellow Fever Therapeutics – Drug Profile Updates
Yellow Fever Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Yellow Fever, H1 2012
Products under Development for Yellow Fever – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012